COVID-19 REINFECTION BETWEEN DOSES OF VACCINATION: CASE REPORT IN A CITY OF BRAZIL’S SOUTHEAST
Abstract
Vaccination against COVID-19 is happening worldwide, with most vaccines requiring 2 doses to reach its maximum potential. It is the most efficient measure to prevent new cases of COVID-19, both of infection and reinfection. This case reports the reinfection of a female receptionist at an urgent care facility, where the research group was testing and monitoring symptoms of patients with flu syndrome, in the city of Belo Horizonte, Minas Gerais, Brasil, where she reinfected between the two preconized doses. Her initial infection occurred in September 2020 and reinfection in February 2021, 14 days after the first dose - both confirmed by RT-PCR - with reportedly worse symptoms on the latter. We warn for the possibility of reinfection episodes even after the first dose of vaccination, differently from what literature stated so far, so that health agents can organize more effective security measures, in a context of viral mutation and of new strains.References
BUSS, L. F.; PRETE-JUNIOR, C. A.; ABRAHIM, C. M. M. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science, v. 371, n. 6526, p. 288-292, 2021.
COSTA, M. S.; SATO, H. I.; ROCHA, R. P. et al. Adjusting the Cut-Off and Maximum Pool Size in RT-qPCR Pool Testing for SARS-CoV-2. Viruses, v. 13, n. 4, p. 557, 2021.
FINTELMAN-RODRIGUES, N.; DA SILVA, A. P.D.; DOS SANTOS, M. C. et al. Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, Brazil. Emerging Infectious Diseases, v. 27, n. 5, p. 1446-1453, 2021.
FREITAS, A. R. R.; BECKEDORFF, O. A.; CAVALCANTI, L. P. G.; SIQUEIRA, A. M.; CASTRO, D. B. de; COSTA, C. F. da et al. The Emergence of Novel SARS-CoV-2 Variant P.1 in Amazonas (Brazil) Was Temporally Associated with a Change in the age and Gender Profile of COVID-19 Mortality. SSRN Electronic Journal, v. 1, n.100021, sept. 2021.
FREITAS, A. R. R.; GIOVANETTI, M.; ALCANTARA, L. C. J. Variantes emergentes do SARS-CoV-2 e suas implicações na saúde coletiva. InterAmerican Journal of Medicine and Health, v. 4, 2021.
GUDBJARTSSON, D. F.; NORDDAHL, G. L.; MELSTED, P. et al. Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine, v. 383, n. 18, p. 1724-1734, 2020.
KOCHHAR, S.; SALMON, D. A. Planning for COVID-19 vaccines safety surveillance. Vaccine, v. 38, n. 40, p. 6194-6198, 2020.
KRAUSE, P. R.; GRUBER, M. F. Emergency Use Authorization of Covid Vaccines — Safety and Efficacy Follow-up Considerations. New England Journal of Medicine, v. 383, n. 19, p. e107, 2020.
SAMANOVIC, M. I.; CORNELIUS, A. R.; GRAY-GAILLARD, S. L. et al. Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. medRxiv Preprint. 2021.
SEOW, J.; GRAHAM, C.; MERRICK, B. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, v. 5, n. 12, p. 1598-1607, 2020.
WIDGE, A. T.; ROUPHAEL, N. G.; JACKSON, L. A. et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, v. 384, n. 1, p. 80-82, 2021.
ZHANG, Y.; ZENG, G.; PAN, H. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases, v. 21, n. 2, p. 181-192, 2021.
Copyright (c) 2021 Iniciação Científica Cesumar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Editorial Board is authorized to make certain changes in the original text to comply with bibliographical norms, orthography and grammar, so that standards in language and style may be maintained. However, the author´s style will be preserved. The concepts developed by the authors are their exclusive concern and responsibility.In case of approval, the e-mail of acceptance will contain a Letter of Copyright with authors´ name, personal data, and signature of all authors.